ShockWave Medical (SWAV)
(Delayed Data from NSDQ)
$330.00 USD
+1.01 (0.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $330.06 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$330.00 USD
+1.01 (0.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $330.06 +0.06 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Zacks News
Is Invesco S&P MidCap 400 Equal Weight ETF (EWMC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EWMC
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
ShockWave Medical (SWAV) Hits 52-Week High: Will it Continue?
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
3 Healthcare Trends to Ride for Longevity
by Andrew Rocco
Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.
Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets
by Zacks Equity Research
Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.
Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Shockwave Medical (SWAV) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 27.16% and 10.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWO
Healthcare: An Essential Sector (3 Stocks to Buy Ahead of Earnings)
by Andrew Rocco
Healthcare stocks are an excellent place to park your money in the current market environment. Due to it's necessity, the sector tends to due well in any economy.
Shockwave Medical (SWAV) Moves 10.6% Higher: Will This Strength Last?
by Zacks Equity Research
Shockwave Medical (SWAV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Pacific Biosciences (PACB) Stock Jumps 18.7%: Will It Continue to Soar?
by Zacks Equity Research
Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Is the Options Market Predicting a Spike in Shockwave Medical (SWAV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Shockwave Medical (SWAV) stock based on the movements in the options market lately.
Shockwave Medical (SWAV) Launches New IVL Catheter in U.S.
by Zacks Equity Research
Shockwave Medical's (SWAV) latest U.S. launch is expected to serve a wider patient pool.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWO
SmileDirectClub (SDC) Q4 Earnings Beat, Gross Margin Down
by Zacks Equity Research
SmileDirectClub (SDC) delivers an improved bottom line and cash flows in the fourth quarter despite a reduction in revenues.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Omnicell (OMCL) delivers earnings and revenues in the fourth quarter exceeding the previously revised outlook amid macroeconomic challenges.
Alcon (ALC) Q4 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
Alcon (ALC) reports impressive CER growth in net sales across all segments in the fourth quarter amid a challenging macroeconomic environment.
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWG
Wall Street Analysts Think Shockwave Medical (SWAV) Could Surge 28.8%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Shockwave Medical (SWAV) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Shockwave Medical's (SWAV) Q4 Earnings Top, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Shockwave Medical (SWAV) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 274.75% and 1.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?